Consistent with an increase in the levels of hepatic GSH, DCHT treatment rescued the reduction in GR and GPX (an antioxidant) activities (Lu, 2013; Scirè et al., 2019) that were depleted in ANIT-induced intrahepatic cholestasis. This evidence concerns the gene STK39 and intrahepatic cholestasis.